Tspan8 is expressed in breast cancer and regulates E-cadherin/catenin signalling and metastasis accompanied by increased circulating extracellular vesicles

Maren Voglstaetter1†, Andreas R Thomsen2,3†, Jerome Nouvel1,4, Arend Koch1, Paul Jank4, Elena Grueso Navarro1†, Tanja Gainey-Schleicher1, Richa Khanduri1, Andrea Groß1, Florian Rossner6, Carina Blaue1, Clemens M Franz2, Marina Veil1, Gerhard Puetz4, Andreas Hippe4, Jochen Dindorf4,10,11, Jubin Kashef12, Wilko Thiele13, Bernhard Homey9, Celine Greco6,15, Claude Boucheix14,15, Andreas Baur10,11, Thalia Erbes16, Cornelius F Waller1, Marie Follo17,18, Ghamartaj Hossein1,19, Christine Sers6, Jonathan Sleeman4,13 and Irina Nazarenko1,3*

1 Institute for Infection Prevention and Hospital Epidemiology; Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
2 Department of Radiation Oncology, Medical Center, University of Freiburg, Freiburg im Breisgau, Germany
3 German Cancer Consortium (DKTK), Partner Site Freiburg and German Cancer Research Center (DKFZ), Heidelberg, Germany
4 Institute of Toxicology and Genetics, Karlsruhe Institute of Technology, Karlsruhe, Germany
5 Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany
6 Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany
7 DFG-Center for Functional Nanostructures, Karlsruhe Institute of Technology, Karlsruhe, Germany
8 Institute of Clinical Chemistry and Laboratory Medicine, University of Freiburg, Freiburg im Breisgau, Germany
9 Department of Dermatology, Medical Faculty, University of Düsseldorf, Düsseldorf, Germany
10 Department of Dermatology, University Hospital Erlangen, Erlangen, Germany
11 Translational Research Center, Friedrich-Alexander-University of Erlangen-Nuernberg, Erlangen, Germany
12 Institute for Photon Science and Synchrotron Radiation, Karlsruhe Institute of Technology (KIT), Eggenstein-Leopoldshafen, Germany
13 Medical Faculty, University of Heidelberg, Mannheim, Germany
14 UMR-S935, Inserm, Université Paris Sud, Université Paris Saclay, Villejuif, France
15 Department of Pain Management and Palliative Care, Necker Hospital, Paris, France
16 Department of Gynecology and Obstetrics, Faculty of Medicine, University of Freiburg, Freiburg, Germany
17 Department of Medicine I, Medical Center, University of Freiburg, Freiburg, Germany
18 Faculty of Medicine, University of Freiburg, Freiburg, Germany
19 Department of Animal Physiology, Laboratory of Developmental Biology, University of Tehran, Tehran, Iran

*Correspondence to: INazarenko, Institute for Infection Prevention and Hospital Epidemiology, Medical Center University of Freiburg, Breisacherstr. 1 5b, 79106 Freiburg, Germany. E-mail: irina.nazarenko@uniklinik-freiburg.de
† These authors contributed equally to this study.
‡ Current address: Developmental Biology Unit, Institute of Biology I, Faculty of Biology, University of Freiburg, 79104 Freiburg, Germany.

Abstract

Tspan8 exhibits a functional role in many cancer types including pancreatic, colorectal, oesophagus carcinoma, and melanoma. We present a first study on the expression and function of Tspan8 in breast cancer. Tspan8 protein was present in the majority of human primary breast cancer lesions and metastases in the brain, bone, lung, and liver. In a syngeneic rat breast cancer model, Tspan8+ tumours formed multiple liver and spleen metastases, while Tspan8− tumours exhibited a significantly diminished ability to metastasise, indicating a role of Tspan8 in metastases. Addressing the underlying molecular mechanisms, we discovered that Tspan8 can mediate up-regulation of E-cadherin and down-regulation of Twist, p120-catenin, and β-catenin target genes accompanied by the change of cell phenotype, resembling the mesenchymal–epithelial transition. Furthermore, Tspan8+ cells exhibited enhanced cell–cell adhesion, diminished motility, and decreased sensitivity to irradiation. As a regulator of the content and function of extracellular vesicles (EVs), Tspan8 mediated a several-fold increase in EV number in cell culture and the circulation of tumour-bearing animals. We observed increased protein levels of E-cadherin and p120-catenin in these EVs; furthermore, Tspan8 and p120-catenin were co-immunoprecipitated, indicating that they may interact with each other. Altogether, our findings show the presence of Tspan8 in breast cancer.
primary lesion and metastases and indicate its role as a regulator of cell behaviour and EV release in breast cancer.

Keywords: breast cancer; Tspan8; mesenchymal–epithelial transition; beta-catenin signalling pathway; tetraspanins; extracellular vesicles; metastases; three-dimensional cell culture

Introduction

The need to enhance understanding of how metastases develop and progress has initiated many studies. The role of epithelial–mesenchymal transition (EMT) has come to the fore, suggesting that a proportion of primary tumour cells acquire mesenchymal properties to pass the basal membrane, disseminate into the blood stream or lymphatic system, and colonise distant organs [1]. Based on this clinical observation, it has also been proposed that a reverse process, so-called mesenchymal–epithelial transition (MET), which triggers cancer cell redifferentiation, takes place in a portion of metastases and supports their growth [2]. Despite controversial discussions and recent research showing that EMT is not important for metastases but does play a role in conferring chemoresistance in lung [3] and pancreatic cancer [4], a plethora of data support the occurrence of EMT–MET-like processes in breast cancer [5]. Whereas primary breast carcinomas, e.g. invasive ductal carcinomas, express mesenchymal markers, their metastases frequently exhibit epithelial features [6]. However, the underlying mechanisms are not yet understood. In this work, we propose a new function of Tspan8 as an EMT–MET regulator in breast cancer.

Tetraspanins are transmembrane proteins that act as membrane scaffolds contributing to the arrangement of proteins in the cell membrane by organising so-called tetraspanin-enriched microdomains (tetraspanin web) [7]. Tetraspanin Tspan8 function is linked to the regulation of cell motility, and is relevant for cancer progression. Up-regulation of Tspan8-coding mRNA has been detected in colorectal, pancreatic [8], gastric [9], and hepatocellular [10] carcinomas, as well as in melanoma [11] and glioma [12]. It is likely that Tspan8 interacts with different proteins in different tumour types. Thus, in pancreatic cancer, CD9, CD151, CD44v6, and integrins CD49c and CD49d, as well as intersectin and clathrin, have been shown to be the main interacting partners of Tspan8 [13]. In colorectal cancer, Tspan8 regulates cell motility and p120-catenin function by interaction with E-cadherin [14]; recently, interaction of Tspan8 with mephrin-β was demonstrated [15]. Furthermore, targeting Tspan8 function may offer benefit as a therapeutic intervention in ovarian [16] and colorectal [17] carcinomas, hence attracting attention to this molecule as a potential drug target. Recently, Tspan8 was identified as a biomarker for a subset of deeply quiescent mammary stem cells (Lgr5+Tspan8hi), whose transcriptome resembled claudin-low breast carcinoma [18], thus indicating a potential role in breast cancer. In this study, we analysed the expression of Tspan8 in breast cancer in primary lesions and in metastases in humans and examined its impact on the EMT–MET programme in breast cancer cells and on the release and function of extracellular vesicles using a syngeneic rat breast cancer model.

Materials and methods

Patient samples

Biopsies were acquired from breast cancer patients and normal breast samples were obtained from individuals undergoing plastic surgery. All samples were taken after the study had been approved by the local ethics committee and written informed patient consent had been obtained. Immunohistochemistry was performed as described in supplementary material, Supplementary materials and methods.

In vivo model

Animal experiments were performed according to regional and national guidelines and approved by the ethics committee. Orthotopic injection of female Fischer rats F344/DuCrI (Charles River, Sulzfeld, Germany) was performed into a mammary fat pad (n = 5 per group, 1 × 10^6 cells). Animals were euthanised after 18 days; organs were prepared to control metastases, and blood was used for extracellular vesicle (EV) preparation as described in supplementary material, Supplementary materials and methods.

Cell lines and cell assays

Detailed information regarding cultivation of different cell lines under 2D and 3D conditions is provided in supplementary material, Supplementary materials and methods.

AFM-based single-cell force spectroscopy

A detailed description of the method is provided in supplementary material, Supplementary materials and methods.
Figure 1. Legend on next page.
Immunofluorescence
Cells were grown in eight-chamber slides (Ibidi, Planegg, Germany), fixed, permeabilised, blocked and incubated with a primary antibody (60 min, 4 °C), washed three times, incubated with a fluorochrome-conjugated secondary antibody (60 min, 4 °C), mounted with Dako mounting medium, and analysed using an LSM510 confocal microscope (Carl Zeiss, Oberkochen, Germany).

Preparation of EVs
EVs were isolated and characterised according to the MISEV requirements [19] as described previously [13] (supplementary material, Supplementary materials and methods; EV-TRACK database number MG3779JM).

Protein and RNA analysis
A detailed description of the method is provided in supplementary material, Supplementary materials and methods.

Statistics
All experiments were carried out in at least triplicates (regardless of intra-assay triplicates) and statistically evaluated by the two-tailed Student’s t-test or Mann–Whitney. P values of less than 0.05 were considered significant.

Results
Tspan8 is expressed in breast cancer primary lesions and in metastases in different organs
While the majority of tetraspanins are ubiquitously expressed, in a healthy organism, the presence of TSPAN8 is mainly restricted to the digestive tract (Figure 1A) [20]. However, TSPAN8 is likely to be up-regulated in different cancer types [21]. To address the possibility of TSPAN8 playing a role in breast cancer, we first tested seven breast cancer cell lines (supplementary material, Table S4) [22] for TSPAN8 expression and observed that only MDA-MB-361 cells derived from brain metastases exhibited high levels of TSPAN8. Other cell lines originating from primary tumours or pleural effusions were found to be Tspan8high/Tspan8low (Figure 1B). We also tested mRNA isolated from cancer patient samples and detected different levels of TSPAN8-coding mRNA in 4/7 primary tumours and 6/7 lymph node metastases, further supporting a role for TSPAN8 in breast cancer (supplementary material, Figure S1). Subsequently, we examined the MDA-MB-231 model, consisting of the parental cell line and two derivatives – 231-BR cells, representing a brain-seeking clone [23], and 231-BCS60 cells, representing a bone-seeking clone [24]. In this model, TSPAN8 was expressed significantly higher in the brain-seeking 231-BR cells than in the parental and the 231-BCS60 cells (Figure 1C), indicating that expression of TSPAN8 may vary in the primary tumour and its metastases.

These first observations prompted us to perform immunohistochemistry in 27 primary human tumours (16 ductal carcinomas, seven lobular carcinomas, and four carcinomas in situ) and in 53 metastases from different organs (30 brain, nine liver, eight bone, and six lung metastases). TSPAN8 was detected in 24/27 primary lesions and in 41/53 metastases; specifically, 18/30 brain metastases and all of the liver, bone, and lung metastases showed TSPAN8-specific staining (Table 1 and Figure 1D). The specimens exhibited a heterogeneous signal and by 5–80% positive cells, the samples were considered positive.

It should be mentioned that to test for a link between TSPAN8 expression in primary tumours and the corresponding metastases, we were able to use 14 samples where both the primary tumour and the metastases originated from the same patient (Table 1). Thus, nine patients with brain metastases, three with liver metastases, and two with bone metastases were examined (Table 1 and Figure 1D). We observed that the expression levels of TSPAN8 in primary tumours and in the corresponding metastases differed from each other, indicating that expression thereof may change during tumour progression.
## Table 1. Immunohistochemistry for Tspan8 in breast cancer primary tumours and in their metastases

| Primary tumour No | Primary tumour                                      | TSPAN8 cytoplasmic | TSPAN8 membrane | Metastasis No | Metastasis | TSPAN8 cytoplasmic | TSPAN8 membrane |
|-------------------|-----------------------------------------------------|--------------------|-----------------|---------------|------------|--------------------|-----------------|
| 1                 | Poorly differentiated, invasive ductal              | 50% +              | –               | 1             | Brain      | 20% +             | 10% +           |
| 2                 | Poorly differentiated, invasive ductal              | 50% +              | –               | 2             | Brain      | –                 | –              |
| 3                 | Poorly differentiated, invasive ductal              | –                  | –               | 3             | Brain      | 10% +             | –              |
| 4                 | Poorly differentiated, invasive ductal              | 70% +              | –               | 4             | Brain      | –                 | –              |
| 5                 | Poorly differentiated, invasive ductal              | –                  | –               | 5             | Brain      | –                 | –              |
| 6                 | Moderately differentiated, invasive ductal         | –                  | –               | 6             | Brain      | –                 | –              |
| 7                 | Moderately differentiated, invasive ductal         | 80% +              | –               | 7             | Brain      | –                 | 10% +           |
| 8                 | Moderately differentiated, invasive ductal         | –                  | –               | 8             | Brain      | –                 | –              |
| 9                 | Poorly differentiated, lymphoendo invasive         | 80% +              | –               | 9             | Brain      | 40% +             | 10% +           |
| 10                | Moderately differentiated, invasive ductal         | 80% +              | single +        | 10            | Liver      | 80% +             | –              |
| 11                | Moderately differentiated, NST                      | 80% +              | –               | 11            | Liver      | 80% +             | –              |
| 12                | Poorly differentiated, invasive ductal             | 80% +              | 10% +           | 12            | Liver      | 80% +             | –              |
| 13                | Moderately differentiated, invasive lobular        | 90% +              | single +        | 13            | Bone       | 50% + *2***       | –              |
| 14                | Moderately differentiated, invasive lobular        | 95% +              | –               | 14            | Bone       | 90% + *2***       | –              |
| 15                | Moderately differentiated, invasive ductal         | 80% +              | –               | No information | 15         | –                 | No information  |
| 16                | Well differentiated, NST                           | 80% +              | –               | No information | 16         | –                 | No information  |
| 17                | Well differentiated, invasive ductal               | 80% +              | –               | No information | 17         | –                 | No information  |
| 18                | Moderately differentiated, NST                     | 80% +              | 5%              | No information | 18         | No information    | No information  |
| 19                | Moderately differentiated, NST                     | 80% +              | –               | No information | 19         | No information    | No information  |
| 20                | Poorly differentiated, invasive ductal             | 80% +              | 20% +           | No information | 20         | No information    | No information  |
| 21                | Moderately differentiated, invasive lobular        | 80% +              | single +        | No information | 21         | No information    | No information  |
| 22                | Moderately differentiated, invasive lobular        | 80% +              | –               | No information | 22         | No information    | No information  |
| 23                | Moderately differentiated, invasive lobular        | 80% +              | –               | No information | 23         | No information    | No information  |
| 24                | DCIS (G2)                                          | 80% +              | –               | No information | 24         | –                 | –              |
| 25                | DCIS (G2)                                          | 80% +              | 20% +           | No information | 25         | –                 | –              |
| 26                | DCIS (G2)                                          | 80% +              | 20% +           | No information | 26         | –                 | –              |
| 27                | DCIS (G2)                                          | 80% +              | single +        | No information | 27         | –                 | –              |

Moderately differentiated, invasive ductal

| No information | 15 Brain | 50% + | – |
| No information | 16 Brain | – | – |
| No information | 17 Brain | – | – |
| No information | 18 Brain | – | – |
| No information | 20 Brain | – | – |
| No information | 21 Brain | – | – |
| No information | 22 Brain | 50% + | 50% + |
| No information | 23 Brain | – | – |
| No information | 25 Brain | – | – |
| No information | 26 Brain | 80% +++ | 40% ++ |
| No information | 27 Brain | 80% + | 5% + |
| No information | 28 Brain | 80% + | – |
| No information | 29 Brain | 80% + | – |
| No information | 30 Brain | 80% + | 5% + |
| No information | 31 Brain | – | – |
| No information | 32 Brain | 80% + | – |
| No information | 33 Brain | 80% + | – |
| No information | 34 Brain | 80% + | – |
| No information | 35 Brain | 80% + | – |
| No information | 36 Brain | 80% + | – |
| No information | 37 Brain | 80% + | 5% + |
| Invasive lobular | 38 Liver | 80% + | – |
| Invasive ductal | 39 Liver | 80% + | – |
| No information | 40 Liver | 80% + | – |
| No information | 41 Liver | 80% + | – |
| No information | 42 Liver | 80% + | 5% + |
| No information | 43 Liver | 80% + | Single + |
| Invasive NST | 44 Lung | 80% + | 10% + |
| Invasive, NST | 45 Lung | 80% ++ | 50% + |
| No information | 46 Lung | 80% + | 50% + |
| No information | 47 Lung | 80% + | – |
| No information | 48 Lung | 80% + | – |
| No information | 49 Lung | 80% + | – |
| No information | 50 Lung | 80% + | Single + |
| No information | 51 Bone | 80% + | – |
| No information | 52 Bone | 80% + | – |
| No information | 53 Bone | 80% + | Single + |
| No information | 54 Bone | 80% + | 10% + |

Data for TSPAN8 expression in the primary tumours and their corresponding metastases detected in the same patient are linked horizontally. Only analysed specimens are numbered: thus, there are 27 primary tumours, and 54 metastases were examined. 70% +: 70% epithelium stained at low intensity; –: no TSPAN8 staining was detected. Intensity was estimated as +: low; ++: moderate; and +++: strong by three pathologists.
Figure 2. Legend on next page.
Overexpression of Tspan8 enhances cell–cell adhesion and proliferation

To assess the direct impact of Tspan8 on breast cancer growth and progression, we chose a syngeneic rat breast cancer model. Overexpression of Tspan8 in the MTPAs [25] parental Tspan8-negative cells led to the formation of compact cell clusters (Figure 2A). We seeded the MTPA-pcDNA3 and MTPA-Tspan8 cells by low density and tracked cluster formation for 12 h. Only MTPA-Tspan8 cells established clusters, suggesting that Tspan8 supports intercellular adhesiveness (Figure 2B). Measurement of cellular adhesion forces using atomic force microscopy by cell retraction [26,27] supported this observation and showed that the MTPA-Tspan8 cells exhibit significantly stronger cell–cell adhesion compared with the MTPA-pcDNA3 cells (Figure 2C). In contrast, MTPA and MTPA-pcDNA3 cells displayed faster cell–matrix adhesion to collagens I and IV, while the MTPA-Tspan8 cells adhered significantly faster to BME (human basement membrane extract) (Figure 2D). The MTPA-Tspan8 cells exhibited approximately three-fold higher efficiency of thymidine incorporation, indicating that Tspan8 also supports cell division (Figure 3E). A similar effect of Tspan8 was observed in the MDA-MB-231 cells stably transfected with Tspan8, indicating the similarity of Tspan8 action in rats and humans (supplementary material, Figure S2).

In cell monolayers wounded by scraping the surface, wound closure was significantly delayed in the MTPA-Tspan8 cells compared with the parental and MTPA-pcDNA3 cells (Figure 2F). Documentation of wound healing by video microscopy revealed that whereas single cells of MTPA and MTPA-pcDNA3 may abandon the cell population and migrate over the scratch, some of the MTPA-Tspan8 cells migrate along the population boundary, while the majority of cells maintain cell–cell contacts, suggesting that Tspan8 impairs wound closure by supporting cell–cell adhesion and thereby preventing scattering of the cell colonies (supplementary material, Movies S1 and S2).

Additionally, we compared the colony formation ability of MTPA-pcDNA3 versus MTPA-Tspan8 cells to determine the impact of Tspan8 on the self-sufficiency of a single cell. Performed under 2D conditions, MTPA cells formed colonies of irregular shape and loose cell–cell contact; in contrast, the MTPA-Tspan8 cells formed tight round colonies, adding strength to the hypothesis that Tspan8 plays a role in cell–cell adhesion (Figure 2G, upper panel). Statistical analysis demonstrated a slightly higher colony-forming ability of the MTPA-pcDNA3 cells compared with the MTPA-Tspan8 cells (Figure 2G, bottom panel), suggesting that Tspan8 does not enhance the self-sufficiency of tumour cells under conventional cell culture conditions.

Under 3D conditions, Tspan8 supports cell–cell adhesion and proliferation in the presence of basal membrane extract (BME), and mediates radiation resistance

To test Tspan8 function under conditions more closely resembling the physiological environment, we employed conventional and customised 3D cell cultures. To examine the ability of the cells for anchorage-independent growth, an agarose liquid overlay was used. The MTPA and MTPA-pcDNA3 cells formed compact spheroids, whereas the MTPA-Tspan8 cells – in contrast to their behaviour under 2D conditions – formed large aggregates with loose cell–cell contacts, indicating impairment of the Tspan8 ability to support cell–cell contact under the conditions being tested (Figure 3A). Similar morphology of the colonies was observed in a conventional soft agar assay (Figure 3B, upper panel); quantitative analysis revealed that Tspan8 overexpression causes a strong reduction of the colony number (Figure 3B, bottom panel), indicating diminished resistance to anoikis by the MTPA-Tspan8 cells. Using recently characterised agarose microwell arrays [28], we tested cell proliferation and observed that, in contrast to 2D, the Tspan8 proliferation-supporting effect was attenuated in a 3D environment (Figure 3C).

Cancer progression involves ECM remodelling and, vice versa, the ECM may mediate cancer cell behaviour [29]. To address the impact of different ECMSs on Tspan8+ and Tspan8− cells, we employed a customised agarose
Figure 3. Tspan8 supports proliferation in BME ECM and mediates radiation resistance in a 3D environment. (A) To characterise aggregate formation, 1000 cells per well were seeded in a 48-well plate coated with 1.5% agarose gel and monitored for 9 days. MTPa cells formed tight cell aggregates, whereas the MTPa-Tspan8 cells lost their ability for cell–cell contact and formed loose cell aggregates (scale bar = 200 μm). (B) Anchorage-independent growth was tested using soft agar colony formation assay. MTPa-Tspan8 cells formed about 300 colonies, whereas nearly 800 colonies were counted for MTPa-pcDNA3 cells, showing a strong negative effect of Tspan8 on anchorage independence (scale bar = 500 μm). (C) A microwell array in six-well plates (upper panel) was used to test cell proliferation under 3D conditions. For quantitative analysis, MTT staining (reflecting metabolic activity of the cells) was used (bottom panel). It showed a slight reduction of proliferation/metabolic activity of MTP-Tspan8 cells compared with the MTPa-pcDNA3 cells (scale bar = 1000 μm). (D) Cell invasion was tested in customised inserts (supplementary material, Figures S3 and S4) for 7 days without ECM (left panel), in collagen I (middle panel), and in BME (right panel, scale bar = 500 μm). (E) Quantitative analysis of cell invasion revealed that in BME, MTPa-Tspan8 cells exhibit a significantly stronger proliferation than the parental MTPa-pcDNA3 cells, showing an increased growth rate after day 4. (F) Gamma-irradiation resistance of 3D cell aggregate was tested using 137Cs with 0.66 Gy/min on day 2 as described in supplementary material, Figure S5. A significantly higher number of the MTPa-Tspan8 aggregates grew upon irradiation than the MTPa-pcDNA3 aggregates. All experiments, if not otherwise mentioned, were repeated at least three independent times.
Tspan8 supports metastases and EV release in breast cancer

Axin2, LEF1, NKD1, and NKD2 [35] were completely abolished in the MTPa-Tspan8 cells, indicating modulation of β-catenin signalling upon Tspan8 overexpression (Figure 4A). On the protein levels, E-cadherin and Tspan8 were significantly increased, while p120-catenin and cadherin-11, the regulators of mesenchymal cell properties [36], were significantly decreased in the MTPa-Tspan8 cells, supporting the notion that Tspan8 mediated MET (Figure 4B). Using immunofluorescence, we observed membrane localisation of Tspan8 and E-cadherin in the MTPa-Tspan8 cells (Figure 4C). While p120-catenin and β-catenin exhibited cytoplasmic localisation in the MTPa cells, they were detected on the cell membrane in the MTPa-Tspan8 cells (Figure 4C). Additionally, β-catenin-specific signals were observed in the nuclei of the MTPa, but not MTPa-Tspan8, cells (Figure 4D, white arrows), which together with the observed down-regulation of the β-catenin target genes in MTPa-Tspan8 cells further supported Tspan8-mediated modulation of the β-catenin signalling pathway. Pronounced membrane staining of Tspan8, E-cadherin, and catenins prompted us to test their potential interaction. Co-immunoprecipitation revealed E-cadherin- and p120-catenin-specific bands in the Tspan8 precipitate. Tspan8 was also detected in the E-cadherin precipitate together with p120-catenin and β-catenin, indicating their association (Figure 4E).

Rescue of Tspan8-induced MET was tested by Tspan8 and E-cadherin knockdown. Partial reversion of the epithelial cell morphology was observed 72 h after transfection with Tspan8- and E-cadherin-specific RNA (Figure 4F, left panel). To control knockdown, western blotting (WB) (Figure 4F, right upper panel) and flow cytometry were performed (Figure 4F, right bottom panel). Significant down-regulation of Tspan8 and E-cadherin upon transfection with Tspan8- and E-cadherin siRNAs was observed, indicating their co-regulation; this was further supported by up-regulation of p120-catenin and β-catenin in both cases. Flow cytometry was performed 48 h after transfection to examine surface expression of Tspan8 (Figure 4F, right bottom panel). The untreated cells and cells transfected with control scrambled siRNA showed 65% and 63% Tspan8 surface expression, respectively (Figure 4F, right bottom panel, blue line, green line). Following Tspan8 siRNA (red line) and E-cadherin siRNA (orange line), the number of positive cells was reduced to 32% and 47%, respectively. These data were consistent with the gene expression analysis (supplementary material, Figure S6).

Next, we tested co-regulation of TSPAN8 and E-cadherin in MDA-MB-361 human breast cancer cells expressing endogenous TSPAN8 and E-cadherin. Knockdown of TSPAN8 and E-cadherin was performed in MDA-MB-361 cells and examined by immunofluorescence and flow cytometry (Figure 4G). Heterogeneous TSPAN8 staining was observed in cells transfected with control siRNA, and siRNAs specific for Tspan8 and E-cadherin. Strong heterogeneity of fluorescence signals hampered their quantification. Therefore, changes in TSPAN8 and E-cadherin surface expression
Figure 4. Legend on next page.
following siRNA treatment were assessed by flow cytometry (Figure 4G, bottom panel). The proportion of Tspan8 strongly-positive cells was calculated. The experiment (G) Knockdown of Tspan8 and E-cadherin was performed in MDA-MB-361 cells followed by immunofluorescence and flow cytometry (Figure 4G, bottom panel). The portion of E-cadherin-positive cells comprised 68.1% and 68% in the non-transfected cells (blue line) and cells transfected with the control siRNA (green line), respectively. E-cadherin surface expression was reduced to 35.2% and 31% after transfection with Tspan8 (red line) and E-cadherin-siRNA (orange line), respectively. Co-regulation of Tspan8 and E-cadherin was also observed at the RNA level, showing that E-cadherin is significantly reduced after Tspan8 knockdown and, vice versa, Tspan8 was reduced after E-cadherin knockdown (supplementary material, Figure S7). However, in contrast to the MTPa cells, neither p120-catenin nor β-catenin was affected by the Tspan8 or E-cadherin siRNAs in the MDA-MB-361 cells (Figure 4H).

Tspan8 supports formation of metastases and EV release in vivo

Next, we tested the effect of Tspan8 on the tumourigenic properties of breast cancer cells in vivo. The MTPa and MTPa-Tspan8 cells were injected orthotopically into mammary fat pads of Fischer rats. No differences in the growth of primary tumours were observed (Figure 5A, upper panel). However, the MTPa-Tspan8 tumours formed multiple metastases in the liver and spleen, suggesting a role for Tspan8 in metastases in breast cancer (Figure 5A). A similar phenomenon was observed when tumour cells were injected intraperitoneally (supplementary material, Figure S8).

Figure 4. Tspan8 induces mesenchymal–epithelial transition. (A) Total RNA was harvested from MTPa, MTPa-pcDNA3, and MTPa-Tspan8 cells, and expression of mRNA coding for E-cadherin, β-catenin, p120-catenin, Twist, and the β-catenin target genes Axin2, LEF1, NDK1, and NDK2 was analysed by RT-qPCR. GAPDH was used as a reference transcript. Overexpression of Tspan8 resulted in up-regulation of E-cadherin, highly significant down-regulation of β-catenin and p120-catenin, and complete abrogation of Twist1, Axin2, LEF1, NDK1, and NDK2 expression. Technical duplicates and biological triplicates were analysed. (B) Cell lysates were prepared from MTPa, MTPa-pcDNA3, and MTPa-Tspan8 cells. WB analysis confirmed the presence of E-cadherin. Densitometry analysis of protein signal intensity performed by ImageJ revealed significantly diminished levels of p120-catenin and cadherin-11 in the MTPa-Tspan8 cells. No significant regulation of β-catenin at the protein level was observed. The experiment was repeated five times. (C) Immunofluorescence analysis of the MTPa and MTPa-Tspan8 cells. Cells were cultured for 24–48 h in chamber slides, fixed, and stained with the indicated antibodies. (D) Z-stack of β-catenin staining was generated for MTPa and MTPa-Tspan8 cells. Red β-catenin-specific fluorescence was detected in the cytoplasm and in the nuclei of MTPa cells, but not of MTPa-Tspan8 cells (small arrow in the Z-stack and arrowhead in the x/y flat bottom image). Immunofluorescence was assessed for four samples independently. (E) Co-immunoprecipitation was performed in the MTPa-Tspan8 cell lysates using antibodies specific to Tspan8, E-cadherin, p120-catenin, and β-catenin. As a negative control, cell lysates were incubated with the corresponding isotype control mouse IgG and β-actin. The experiment was performed three times. (F) Rescue of Tspan8-induced MET was tested by Tspan8 and E-cadherin knockdowns. Bright-field images were taken 72 h after siRNA transfection of MTPa-Tspan8 cells with siRNA. To assess knockdown, proteins were harvested 48 h post-transfection, analysed by WB (right upper panel) and quantified using ImageJ (right middle panel). To assess surface expression, flow cytometry was performed 48 h after transfection (bottom panel). (G) Knockdown of Tspan8 and E-cadherin was performed in MDA-MB-361 cells followed by immunofluorescence and flow cytometry. Heterogeneous Tspan8 staining was observed in cells transfected with control siRNA, and siRNAs specific for Tspan8- and E-cadherin. The experiment was performed three times and representative images are shown. Changes in Tspan8 and E-cadherin surface expression after siRNA were assessed by flow cytometry (bottom panel). The proportion of Tspan8 strongly-positive cells was calculated. The experiment was repeated twice; representative diagrams are shown. (H) MDA-MB-361 cells were transfected with scramble-siRNA and Tspan8-siRNA; proteins were harvested 48 h post-transfection and analysed by WB followed by densitometry analysis using ImageJ. Both Tspan8 and E-cadherin were significantly down-regulated, while neither β-catenin nor p120-catenin was affected (bottom panel).
Figure 5. Tspan8 supports metastases and mediates a significant increase in EV number in the circulation in vivo. (A) Orthotopic injection of rats was performed using $1 \times 10^6$ MTPa or MTPa-Tspan8 cells per animal; cells were injected into the mammary fat pad (five animals per group). At day 18, animals were sacrificed and organs isolated. Representative images of primary tumours, liver, and spleen are shown. Pictures were taken and metastases counted using ImageJ. (B) Immunofluorescence was performed on frozen sections of primary tumours and liver and spleen specimens from both the animals harbouring MTPa- and those harbouring MTPa-Tspan8 tumours. (C) EVs were collected from rat blood and measured by NTA. Significantly higher numbers of EV were detected in the blood of rats injected with MTPa-Tspan8 cells. (D) Transmission electron microscopy of EV preparations revealed vesicular structures typical for EVs isolated from blood. (E) EVs were lysed and equal amounts of proteins were loaded for WB analysis and tested with CD9, Alix, and Tspan8 antibodies. No differences in CD9 and Alix protein amounts were observed in control animals and in animals harbouring MTPa- or MTPa-Tspan8 tumours. (F) Flow cytometry analysis of EVs. Tspan8, CD9, and CD81 were tested and the percentage of positive EVs and the MFI value were counted. Strong differences in the MFI values between the origin of EVs from control animals (green line) and the origin of EVs from MTPa (blue line) and MTPa-Tspan8 (red line) animals were noticed, showing a strong increase in the MFI of Tspan8 and CD81 in EVs derived from MTPa-Tspan8 animals. Flow cytometry was performed twice and representative images are shown.
with the WB data; however, the mean fluorescence intensity (MFI) values for Tspan8 and CD81 were strongly increased in EVs isolated from the blood of MTPa-Tspan8 animals, compared with the MTPa and control animals (Figure 5F and supplementary material, Figure S11), which was consistent with the overall increase in EV number in MTPa-Tspan8 animals.

**Tspan8 modulates EV release and function in vitro**

To test directly a role for Tspan8 in the regulation of EV release, we isolated EVs from cultures of MTPa or MTPa-Tspan8 cells. Electron microscopy showed typical exosome-like structures of 60–100 nm diameter in EV preparations (Figure 6A). Consistent with the observations in vivo, NTA measurements showed a significant increase in the number of EVs from MTPa-Tspan8 cells compared with MTPa cells. We observed both Tspan8- and E-cadherin-specific bands in the MTPa-Tspan8 EVs tested by WB (Figure 6C). Furthermore, recruitment of p120-catenin to EVs was significantly increased in the presence of Tspan8 (Figure 6F). Therefore, we tested their potential interaction in EVs using co-immunoprecipitation. Similar to the results in cells, E-cadherin and p120-catenin were obtained in the Tspan8 precipitates (Figure 6D), supporting their interaction in EVs. Additionally, interaction between E-cadherin, p120-catenin, and β-catenin was detected. To test a direct contribution by Tspan8 to recruitment of the E-cadherin/catenin complex to the EVs, we transfected MDA-MB-361 cells with control or Tspan8-specific siRNA (Figure 6E). We observed a significant reduction of E-cadherin, p120-catenin, and β-catenin in EVs after Tspan8 knockdown, further corroborating our hypothesis. The function of these EVs in tumour progression remains to be explored. However, it is noteworthy that treatment of the parental MTPa cells with EVs released by the MTPa-Tspan8 cells revealed their ability to suppress the expression of p120-catenin and Twist encoding genes, and to diminish the expression of β-catenin target genes in the parental cells, adding strength to the hypothesis that Tspan8 impacts the EV amount and may have a role in the regulation of EV content and function in breast cancer (Figure 6F).

**Discussion**

On examining TSPAN8 expression in human breast cancer specimens, we observed great variations in the TSPAN8 expression levels within one specimen and between primary lesions and metastases originating from the same patient. Also, in the rat model, the liver metastases revealed heterogeneous Tspan8 staining. This observation is consistent with the overall models of tumour heterogeneity and plasticity explaining variations occurring within one lesion as a consequence of genetic and epigenetic changes during tumour progression, which allows cancer cells to adapt to a changing microenvironment [42]. This model is completed by the postulated intra-tumour hierarchy and cancer stem cells (CSCs) [43,44]. It remains to be explored whether Tspan8 may change the tumourigenic properties of breast cancer CSCs; however, preliminary tests demonstrated that TSPAN8 is not expressed in cultures of the breast cancer stem-like cells (data not shown) [45]. Further investigation will be required to understand the molecular mechanisms of TSPAN8 up-regulation in breast cancer cells. Hence, several repressors and activators of TSPAN8, such as GSK3β, IQGAP1, TPT1, LCMR1, PTEN, and p53, were recently identified in melanoma [46,47] which could potentially be involved in the regulation of TSPAN8 expression in breast cancer. Thus, while wild-type p53 suppresses TSPAN8 expression [46], its somatic mutations occurring in breast cancer [48] may be one of the reasons for the re-expression of TSPAN8 in a portion of breast cancer cells in primary lesions or metastases. Experimental data will be required to test this hypothesis.

Furthermore, different intracellular locations of TSPAN8 in the cytoplasm and on the membrane were observed, as has already been described for colorectal cancer [14]. Another tetraspanin, namely CD151, was reported to exhibit membrane and cytoplasmic localisation in breast cancer [49]. Because the intracellular traffic routes and intracellular localisation of tetraspanins are strongly dependent on external stimulation [50], rearrangement of tetraspanin localisation in tumour cells may have functional and, consequently, therapeutic effects. Providing an answer to these questions remains the subject of future investigations.

Here, we addressed the molecular mechanisms of TSPAN8 action in breast cancer cells. Overexpressed in breast cancer cells, Tspan8 induced E-cadherin expression and mediated a strong down-regulation of Twist and β-catenin target genes. Similar to colorectal cancer, co-immunoprecipitation experiments showed the interaction between Tspan8, E-cadherin, and p120-catenin [14]. However, whereas Tspan8 is functionally linked to cell migration in colorectal cancer and abrogates E-cadherin function by collaborating with p120-catenin and α2β1 integrin [14], in breast cancer Tspan8 is likely to act together with E-cadherin, regulating cell–cell adhesion and proliferation. Interestingly, the role of E-cadherin as a tumour suppressor was recently reconsidered because of its ability to support metastatic potential and cell proliferation via the activation of NF-κB [51]. The link between Tspan8 and NF-κB has not yet been explored. However, also in other cancer types, Tspan8 can act as a regulator of proliferation, motility, and invasiveness [9]. Similarly, another tetraspanin, CD151, may exhibit multiple effects including regulation of proliferation, motility, and morphogenesis [52]. Furthermore, CD151 – mostly characterised as a tumour- and metastasis-promoting tetraspanin [53] – was also reported to build a complex with the α3β1 integrin, suppressing ovarian tumour growth by inhibiting Slug-dependent EMT and supporting cell–cell adhesion [54]. These data are consistent
Figure 6. Legend on next page.
with the hypothesis that the biological effects of tetraspanins are determined by their interacting partners [55,56]. It seems that Tspan8 mediates cell motility via collaboration with integrins αβ6/4 in pancreatic cancer [57], α3β1 in gliomas [58], and α2β1 in colorectal cancer [14]. Interaction with E-cadherin resulted in a functional switch of Tspan8 in breast cancer. Alongside increased cell–cell adhesion, Tspan8 supported cell–matrix adhesion to the BME. Since cell–cell and cell–matrix adhesion are functionally linked to each other and involved, alongside cadherins, also integrins [59], a connection between Tspan8 and integrins in breast cancer, as is already known from other cancer types [14,57,58], is possible. It may also explain the observed increase of proliferation in the 3D matrix in BME as a physiological response of the cells on signalling across the adhesive network [59].

Addressing the question of the selective advantages mediated by TSPAN8 in breast cancer, we observed that Tspan8+ cells exhibit significantly greater radiation resistance compared with control Tspan8−mesenchymal-like cells, suggesting that MET may also be linked to radiation resistance. In line with this suggestion, up-regulation of Snail, an EMT trigger, was linked to decreased radiation resistance in MCF7 cells [60]. Integrin α6, which is involved in radiation resistance in breast cancer [61], may also be involved in Tspan8-dependent radiation resistance as its interacting partner [57]. Taking into account that cranial radiation resistance remains one of the leading therapies applied for treatment of brain metastases [32], the presence of Tspan8 may be critical for a response to radiation therapy. Consequently, TSPAN8 inhibition, which has been successfully tested for ovarian and colorectal cancer with TSPAN8 inhibitory antibodies [16,17], may be advantageous for therapy of TSPAN8 metastases.

In addition to regulation of the cell behaviour, Tspan8 mediated a substantial increase in the number of EVs and contributed to the recruitment of its interacting partners to the EVs, consistent with our earlier findings [13]. In line with the evidence that Tspan8 may regulate EV content, we have also provided a useful first indication of the function of these EVs, which will, however, require further investigation. Positive results for testing Tspan8 in EVs by flow cytometry and the observed increase in Tspan8 fluorescence intensity in EVs from the blood of Tspan8 tumour-bearing animals indicate the first hint towards the potential of Tspan8 as a non-invasive biomarker for breast cancer, which would be useful to address in a clinical study.

To sum up, we have described here the first study on TSPAN8 in breast cancer and have demonstrated the impact of Tspan8 on adhesion, proliferation, radiation resistance, and EV release. First hints towards the molecular mechanisms of Tspan8 action and involvement of E-cadherin were provided. These results warrant further investigation of Tspan8 in breast cancer towards the understanding of molecular mechanisms and testing the value of Tspan8 as a therapeutic target and a non-invasive biomarker.

Acknowledgements

Special thanks are due to Margot Zöller (German Cancer Research Center and Heidelberg University Hospital) for providing an antibody for rat Tspan8 and for expertise on Tspan8 and exosomes; to Andreas Hecht (Albert-Ludwigs University Freiburg) for expertise and advice on analysing the β-catenin signalling pathway; to Patricia Steeg (NCI, CCR) for providing MDA-MB-231-BR cells; to the division of Antony Lucci, especially Balraj Singh and Patricia Thomas (Anderson Cancer Centre, Texas, USA), for providing the BSC60 MDA-MB-231 sub-line; to Christine Aldrian for technical support; and to Deborah Lawrie-Blum for proof-reading the manuscript. This work was funded by the German Research Foundation (DFG/grant No NA-870/1-1), H2020-MSCA-ITN-2016 TRAIN-EV (grant No 722148); the Research Commission of the University of Freiburg, Faculty of Medicine (grant No 3095170002), ERA-RusPlus ID110 ExoDiags, BMWi ZIM Collaboration Project (grant No KF2979902CR4) and BMBF IB-GUS/RUS ExoNanSens to IN; and the German Research Foundation (DFG) DFG-FOR 1756 to JK and CMF.

Figure 6. Tspan8 mediates increased EV release in vitro and supports recruitment of E-cadherin and catenins to EVs. (A) Transmission electron microscopy of EVs released by the MTPa and MTPa-Tspan8 cells. Scale bar equals 500 nm in the large panel and 100 nm in the image with higher magnification. (B) NTA was done with each of the samples isolated and a representative image is shown. Statistical analysis of four independent measurements showed a highly significant increase in EV number (right panel). (C) MDA-MB-361 cells were transfected either with control siRNA or with Tspan8-siRNA; EVs were isolated 48h post-transfection and analysed by WB followed by densitometry analysis using ImageJ. GAPDH was used as a loading control. (D) Co-immunoprecipitation was performed in the MTPa-Tspan8 EVs using antibodies specific to Tspan8, E-cadherin, p120-catenin, and β-catenin. As a negative control, EV lysate was incubated with the corresponding isotype control mouse IgG and protein G Sepharose. The experiment was performed three times. (E) MDA-MB-361 cells were transfected either with control siRNA or with Tspan8-siRNA; EVs were isolated 48 h post-transfection and analysed by WB followed by densitometry analysis using ImageJ. GAPDH was used as a loading control. (F) Functional analysis with EVs released from the MTPa-Tspan8 cells was performed. The EVs cells were treated with the MTPa-Tspan8 EVs (5 μg/ml) for 5 days. As controls, MTPa cells were also treated with conditioned cell culture medium (MTPa-Tspan8 CM) and with EV-depleted cell culture medium (MTPa-Tspan8 EV-depl CM) in order to discriminate between EV-specific and EV-non-specific effects. At day 6, the cells were lysed and RNA was isolated and analysed using RT-qPCR. Expression of Tspan8, E-cadherin, β-catenin, p120-catenin, Twist, and the β-catenin target genes Axin2, LEF1, NKD1, and NKD2 was examined. Significant down-regulation of p120-catenin, Twist, NKD1, and NKD2, and up-regulation of Tspan8 were observed, indicating that MTPa-Tspan8 EVs may affect features of the MTPa parental cells.
Author contributions statement

MVo, ART, JN, EG-N, TG-S, AG, PJ, FR, CF, CB, MVe, AH, JD, CG, JK, and WT performed experiments and contributed to data analysis and writing the manuscript. BH, GP, GH, CW, CB, AB, TE, CS, and JS contributed to data analysis and writing the manuscript. IN designed and supervised this study, analysed data, and wrote the manuscript.

References

1. Kalluri R, Weinberg RA. The basics of epithelial–mesenchymal transition. J Clin Invest 2009; 119: 1420–1428.
2. Brabletz T. To differentiate or not – routes towards metastasis. Nat Rev Cancer 2012; 12: 425–436.
3. Fischer KR, Durrans A, Lee S, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 2015; 527: 472–476.
4. Zheng X, Carstens JL, Kim J, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 2015; 527: 525–530.
5. Bill R, Christofori G. The relevance of EMT in breast cancer metastasis: correlation or causality? FEBs Lett 2013; 589: 1577–1587.
6. Chao YL, Shepard CR, Wells A. Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer 2010; 9: 179.
7. Charrin S, Jouannet S, Boucheix C, et al. Tetraspanins at a glance. J Cell Sci 2014; 127: 3641–3648.
8. Claas C, Seiter S, Claas A, et al. Association between the rat homologue of CO-029, a metastasis-associated tetraspan molecule and consumption coagulopathy. J Cell Biol 1998; 141: 267–280.
9. Zha HY, Wu YL, Zheng W, et al. CO-029 is overexpressed in gastric cancer and mediates the effects of EGF on gastric cancer cell proliferation and invasion. Int J Mol Med 2015; 35: 798–802.
10. Kanetaka K, Sakamoto M, Yamamoto Y, et al. Overexpression of tetraspanin CO-029 in hepatocellular carcinoma. J Hepatol 2001; 35: 637–642.
11. Berther-Vergnes O, El Kharbili M, dela Fouchardiere A, et al. Expression profiles of human melanoma cells with different invasive potential reveal TSPAN8 as a novel mediator of invasion. Br J Cancer 2011; 104: 155–165.
12. Pan SJ, Wu YB, Cai S, et al. Over-expression of tetraspanin 8 in malignant glioma regulates tumor cell progression. Biochem Biophys Res Co 2015; 458: 476–482.
13. Nazarenko I, Rana S, Baumann A, et al. Cell surface tetraspan Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res 2010; 70: 1668–1678.
14. Greco C, Bralet MP, Ailane N, et al. E-cadherin/p120-catenin and Tetraspanin CO-029 cooperate for cell motility control in human colon carcinoma. Cancer Res 2010; 70: 7674–7683.
15. Schmidt F, Muller M, Prox J, et al. Tetraspanin 8 is an interactor of the metalloprotease mempin β within tetraspanin-enriched microdomains. Biol Chem 2016; 397: 857–869.
16. Park CS, Kim TK, Kim HG, et al. Therapeutic targeting of tetraspanin8 in epithelial ovarian cancer invasion and metastasis. Oncogene 2016; 35: 4540–4548.
17. Kim TK, Park CS, Jeoung MH, et al. Generation of a human antibody that inhibits TSPAN8-mediated invasion of metastatic colorectal cancer cells. Biochem Biophys Res Commun 2015; 468: 774–780.
18. Fu NY, Rios AC, Pal B, et al. Identification of quiescent and spatially restricted mammary stem cells that are hormone responsive. Nat Cell Biol 2017; 19: 164–176.
19. Lotvall J, Hill AF, Hochberg F, et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles 2014; 3: 26913.
20. Maisonnial-Besset A, Witkowski T, Navarro-Teulon I, et al. Tetraspanin 8 (TSPAN 8) as a potential target for radioimmunotherapy of colorectal cancer. Oncotarget 2017; 8: 22034–22047.
21. Uhlen M, Fagerberg L, Hallström BM, et al. Proteomics. Tissue-based map of the human proteome. Science 2015; 347: 1260419.
22. Dai X, Cheng H, Bai Z, et al. Breast cancer cell line classification and its relevance with breast tumor subtyping. J Cancer 2017; 8: 3313–3314.
23. Yoneda T, Williams PI, Hiraga T, et al. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. JBM 2001; 16: 1486–1495.
24. Singh B, Irving LR, Tai K, et al. Overexpression of COX-2 in celecoxib-resistant breast cancer cell lines. J Surg Res 2010; 163: 235–243.
25. Stock PA, Nicolson GL. Cell surface glycoproteins of 1376NF mammary adenocarcinoma clones of differing metastatic potentials. Exp Cell Res 1983; 147: 255–267.
26. Gadzenko T, Franz TM. Studying early stages of fibroconnect fibrillogenesis in living cells by atomic force microscopy. Mol Biol Cell 2015; 26: 3190–3204.
27. Tauberberger A, Cisneros DA, Friedrichs J, et al. Revealing early steps of α2β1 integrin-mediated adhesion to collagen type I by using single-cell force spectroscopy. Mol Biol Cell 2007; 18: 1634–1644.
28. Thomsen AR, Aldrian C, Bronspt P, et al. A deep conical agarose microwell array for adhesion independent three-dimensional cell culture and dynamic volume measurement. Lab Chip 2017; 18: 179–189.
29. Barkan D, Green JE, Chambers AF. Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur J Cancer 2010; 46: 1181–1188.
30. Wolf K, Alexander S, Schacht V, et al. Collagen-based cell migration models in vitro and in vivo. Semin Cell Dev Biol 2009; 20: 931–941.
31. Kimbug S, Loman N, Hedenfalk I. Clinical and molecular complexity of breast cancer metastases. Semin Cancer Biol 2015; 35: 85–95.
32. Smart D, Garcia-Glaessner A, Palmieri D, et al. Analysis of radiation therapy in a model of triple-negative breast cancer brain metastasis. Clin Exp Metastasis 2015; 32: 717–727.
33. Hahnel A, Wichmann H, Kappler M, et al. Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells. Radiat Oncol 2010; 5: 82.
34. Speers C, Zhao S, Liu M, et al. Development and validation of a novel radiosensitivity signature in human breast cancer. Clin Cancer Res 2015; 21: 3667–3677.
35. Watanabe K, Biesinger J, Salmons ML, et al. Integrative ChiP-seq/microarray analysis identifies a CTNNB1 target signature enriched in intestinal stem cells and colon cancer. PloS One 2014; 9: e92317.
36. Birullto C, Pham H, Morvndi S, et al. Cadherin-11 is a cell surface marker up-regulated in activated pancreatic stellate cells and is involved in pancreatic cancer cell migration. Am J Pathol 2017; 187: 146–155.
37. Peinado H, Aleckovic M, Lavotshkin S, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 2012; 18: 883–891.
38. Costa-Silva B, Aiello NM, Ocean AJ, et al. Pancreatic cancer exosomes initiate pro-metastatic niche formation in the liver. Nat Cell Biol 2015; 17: 816–826.
39. Peinado H, Zhang H, Matei IR, et al. Pre-metastatic niches: organ-specific homes for metastases. *Nat Rev Cancer* 2017; 17: 302–317.

40. Termini CM, Gillette JM. Tetraspanins function as regulators of cellular signaling. *Front Cell Dev Biol* 2017; 5: 34.

41. Keller S, Ridinger J, Rupp AK, et al. Body fluid derived exosomes as a novel template for clinical diagnostics. *J Transl Med* 2011; 9: 86.

42. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. *Nature* 2013; 501: 328–337.

43. Battelli E, Clevers H. Cancer stem cells revisited. *Nat Med* 2017; 23: 1124–1134.

44. Brabletz T. EMT and MET in metastasis: where are the cancer stem cells? *Cancer Cell* 2012; 22: 699–701.

45. Metzger E, Stepputis SS, Strietz J, et al. KDM4 inhibition targets breast cancer stem-like cells. *Cancer Res* 2017; 77: 5900–5912.

46. Aagaesse G, Barbollat-Boutrand L, El Kharbili M, et al. p53 targets TSPAN8 to prevent invasion in melanoma cells. *Oncogene* 2017; 6: e309.

47. Aagaesse G, Barbollat-Boutrand L, Sulpice E, et al. A large-scale RNAs screen identifies LCMR1 as a critical regulator of Tspan8-mediated melanoma invasion. *Oncogene* 2017; 36: 446–457.

48. Liu Y, Yang B, Zhang X, et al. The gene mutation spectrum of breast cancer analyzed by semiconductor sequencing platform. *Pathol Oncol Res* 2018. https://doi.org/10.1007/s12533-018-0522-5 [Epub ahead of print].

49. Yang XH, Richardson AL, Torres-Arroyo ML, et al. CD151 accelerates breast cancer by regulating α6 integrin function, signaling, and molecular organization. *Cancer Res* 2008; 68: 3204–3213.

50. Rana S, Claas C, Kretz CC, et al. Activation-induced internalization differs for the tetraspanins CD9 and Tspan8: impact on tumor cell motility. *Int J Biochem Cell Biol* 2011; 43: 106–119.

51. Park SY, Shin JH, Kee SH. E-cadherin expression increases cell proliferation by regulating energy metabolism through nuclear factor-kappaB in AGS cells. *Cancer Sci* 2017; 108: 1769–1777.

52. Zheng ZZ, Liu ZX. CD151 gene delivery increases eNOS activity and induces EVCV304 migration, proliferation and tube formation. *Acta Pharmacol Sin* 2007; 28: 66–72.

53. Romanska HM, Berditchevski F. Tetraspanins in human epithelial malignancies. *J Pathol* 2011; 223: 4–14.

54. Baldwin LA, Hoff JT, Lefringhouse J, et al. CD151–α3β1 integrin complexes suppress ovarian tumor growth by repressing slug-mediated EMT and canonical Wnt signaling. *Oncotarget* 2014; 5: 12203–12217.

55. Hemler ME. Tetraspanins promote multiple cancer stages. *Nat Rev Cancer* 2014; 14: 49–60.

56. Zoller M. Tetraspanins: push and pull in suppressing and promoting metastasis. *Nat Rev Cancer* 2009; 9: 40–55.

57. Herlevsen M, Schmidt DS, Miyazaki K, et al. The association of the tetraspan D6.1A with the α6β4 integrin supports cell motility and liver metastasis formation. *J Cell Sci* 2003; 116: 4373–4390.

58. Pan SJ, Zhan SK, Pan YX, et al. Tetraspan 8–riCTOR–integrin α3 complex is required for glioma cell migration. *Int J Mol Sci* 2015; 16: 5363–5374.

59. Weber GF, Bjerke MA, DeSimone DW. Integrins and cadherins join forces to form adhesive networks. *J Cell Sci* 2011; 124: 1183–1193.

60. Mezencev R, Matyunina LV, Jabbari N, et al. Snail-induced epithelial-to-mesenchymal transition of MCF-7 breast cancer cells: systems analysis of molecular changes and their effect on radiation and drug sensitivity. *BMC Cancer* 2016; 16: 236.

61. Hu T, Zhou R, Zhao Y, et al. Integrin α6/Akt/Erk signaling is essential for human breast cancer resistance to radiotherapy. *Sci Rep* 2016; 6: 33376.

**SUPPLEMENTARY MATERIAL ONLINE**

Supplementary materials and methods

**Figure S1.** RT–qPCR analysis of TSPAN8 encoding mRNA in human tumours

**Figure S2.** Impact of Tspan8 on adhesion and proliferation of human breast cancer cells MDA-MB-231

**Figure S3.** Customised agarose device to test impact of different ECM on cell growth and behaviour

**Figure S4.** Radiation resistance test of MTPa-pcDNA3 and MTPa-Tspan8 cells under 3D conditions

**Figure S5.** Impact of Tspan8 on radiation sensitivity using conventional 2D colony formation assays

**Figure S6.** Co-regulation of Tspan8 and E-cadherin expression in MTPa-Tspan8 cells

**Figure S7.** Co-regulation of Tspan8 and E-cadherin expression in MDA-MB-361 cells

**Figure S8.** Primary tumour and metastases in liver and spleen of rats after intraperitoneal injection of MTPa and MTPa-Tspan8 cells in Fischer rats

**Figure S9.** NTA analysis of blood samples of rats after orthotopic injection of MTPa and MTPa-Tspan8 cells

**Figure S10.** Nanoparticle tracking analysis (NTA) and dynamic light scattering (DLS) of extracellular vesicles (EVs) isolated from blood of rats after intraperitoneal injection of MTPa and MTPa-Tspan8 cells

**Figure S11.** Settings for flow cytometry analysis of EVs isolated from the blood of tumour-bearing animals

**Table S1.** List of the antibodies used (mentioned in supplementary material, Supplementary materials and methods)

**Table S2.** List of the primers used for qPCR (mentioned in supplementary material, Supplementary materials and methods)

**Table S3.** List of the siRNAs used for transient gene knockdown

**Table S4.** Human breast cancer cell lines tested for TSPAN8 expression

**Movie S1.** Time lapse of wound closure by MTPa cells

**Movie S2.** Time lapse of wound closure by MTPa-Tspan8 cells